Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
医学
皮肤病科
大疱性表皮松解症
作者
Shireen V. Guide,Mercedes E. González,Işın Sinem Bağcı,Brittani Agostini,Hubert Chen,Gloria Feeney,Molly Steimer,Binoy Kapadia,Kunju Sridhar,Lori Quesada Sanchez,Franshesca Gonzalez,Matthew Van Ligten,Trevor J. Parry,Surya Chitra,Lisa A. Kammerman,Suma Krishnan,M. Peter Marinkovich
Complete wound healing at 3 and 6 months in patients with dystrophic epidermolysis bullosa was more likely with topical administration of B-VEC than with placebo. Pruritus and mild systemic side effects were observed in patients treated with B-VEC. Longer and larger trials are warranted to determine the durability and side effects of B-VEC for this disease. (Funded by Krystal Biotech; GEM-3 ClinicalTrials.gov number, NCT04491604.).
PDF的下载单位、IP信息已删除
(2025-6-4)
和谐的友梅
GingerF
完美的翼
tiptip
Qin
火星上的菲鹰
Kao
乐空思
專注完美近乎苛求
无极微光
OK
俭朴的甜瓜
Copyright
诚心香菇
Akim
tt
皖公网安备34019202002308
